BioWorld

May 17, 2007

FDA Panel Votes Favorably For FluMist In Young Children

GAITHERSBURG, Md. - FluMist should be used in children between 1 and 5 years old, a majority of FDA advisors recommended Wednesday, supporting MedImmune Inc.'s bid to expand use of the live influenza virus vaccine. (BioWorld Today) Read More

Medarex's UltiMAb Lands Its 2nd Partnership With Organon

Chance Discovery Shows Mammalian Regeneration

Inovio Offering Brings In $16.2M For Electroporation Technologies

Other News To Note

Clinic Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...